X-tosis is at the forefront of developing innovative therapies aimed at treating neurodegenerative diseases such as Alzheimer's and Parkinson's by specifically targeting mitochondrial dysfunction. The company's XTS compounds focus on inhibiting the oligomerization of VDAC1, a mitochondrial protein that plays a significant role in cell death and inflammation associated with these disorders. This targeted approach is built on over two decades of research and has shown promising results in preclinical studies, demonstrating improvements in learning and memory, reduced neuronal loss, and enhanced mitochondrial function. By addressing the underlying mechanisms of neurodegeneration, X-tosis aims to halt disease progression and improve the quality of life for patients.

The technology behind X-tosis's approach is centered on the critical role of VDAC1 in mitochondrial health. By disrupting the oligomerization of this protein, XTS compounds not only restore mitochondrial function but also mitigate inflammation and neuronal death linked to neurodegenerative diseases. With evidence supporting the efficacy of these compounds across various conditions associated with VDAC1 overexpression, X-tosis is positioned to reshape the future of healthcare by shifting the focus from merely managing symptoms to modifying the disease itself. This innovative strategy represents a significant advancement in the treatment landscape for neurodegenerative diseases.

At X-Tosis, we are pioneering the future of Alzheimer's treatment by targeting the disease at its core. 
Our innovative compound, VBIT, specifically inhibits the protein VDAC1, effectively halting mitochondrial dysfunction—a primary factor in Alzheimer's progression. 
This groundbreaking approach aimed at stopping the progression of Alzheimer's and saving lives.

Our mission is to stop Alzheimer's disease, not just slow it down.

X-tosis

Company Details